Home Journals Articles Updates About
CN
image
收藏切换
Attitude towards genetic testing for breast cancer susceptibility genes and choice of prevention strategies in Chinese women with or without breast cancer
收藏切换
PDF
Xue Yu1, Furong Kou2, Yuntao Xie1, 2, 3
Cancer Biology & Medicine | 2025, 22(1) : 28 - 32
Less
收藏切换
Cancer Biology & Medicine | 2025, 22(1): 28-32
• Letter •
Attitude towards genetic testing for breast cancer susceptibility genes and choice of prevention strategies in Chinese women with or without breast cancer
Full
Xue Yu1, Furong Kou2, Yuntao Xie1, 2, 3
Affiliations
  • 1Department of Breast Surgery, Peking University International Hospital, Beijing 102206, China
  • 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Comprehensive Clinical Trial Ward, Peking University Cancer Hospital & Institute, Beijing 100142, China
  • 3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Familial and Hereditary Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China
About Author:

*These authors contributed equally to this study.

Author contributions

Conceived and designed the analysis: Yuntao Xie

Collected the data: Xue Yu, Furong Kou

Contributed data or analysis tools: Xue Yu, Furong Kou

Performed the analysis: Furong Kou

Wrote the paper: Furong Kou, Yuntao Xie.

Published: 2025-01-15 doi: 10.20892/j.issn.2095-3941.2024.0519
Outline
收藏切换
Xue Yu, Furong Kou, Yuntao Xie. Attitude towards genetic testing for breast cancer susceptibility genes and choice of prevention strategies in Chinese women with or without breast cancer[J]. Cancer Biology & Medicine, 2025 , 22 (1) : 28 -32 . DOI: 10.20892/j.issn.2095-3941.2024.0519
Full Text
Less
Breast cancer (BC) is now the most common cancer and the fifth leading cause of cancer-associated mortality among women in China1. Germline pathogenic variants (PVs) of BC susceptibility genes, such as the well-known BRCA1/2 genes, increase the risk of BC and other cancers (ovarian and pancreatic cancer)2,3. Recent studies have demonstrated substantial benefits of poly (adenosine diphosphate ribose) polymerase inhibitors in the treatment of BC patients who carry BRCA1/2 PVs4.
Therefore, genetic testing for BC susceptibility genes has become an essential component of health care and has implications for screening, cancer prevention and therapeutic recommendations in individuals harboring PVs5. A better understanding of attitudes towards genetic testing and factors affecting utilization could influence clinical practice.
The demands of genetic testing have increased worldwide due to the feasibility of new gene sequencing techniques and the improved efficacy of targeted therapy. Previous studies have demonstrated a high level of interest in genetic testing in Western countries with 60%–90% of the population considering genetic testing6–8. Attitudes towards genetic testing varies based on individual characteristics. Specifically, individuals with the following characteristics have favorable attitudes towards genetic testing: younger age; a higher level of genetic knowledge with higher education; and higher income7,8. Furthermore, there are various motivations for genetic testing in different cultures, including awareness of a child’s risk for cancer, knowing and reducing one’s personal cancer risk, detecting cancer early, and helping family members make better health decisions7,9. However, no published studies have described the attitudes towards genetic testing for BC susceptibility gene and the influence on prevention strategies in the Chinese population.
We conducted a prospective survey study to explore attitudes and the factors influencing genetic testing for BC susceptibility genes, as well as prevention strategy choices when Chinese women carry PVs. We recruited women with or without BC from the Department of Breast Surgery at Peking University International Hospital between May 2020 and March 2023. The workflow of patient selection is shown in Figure S1. Participants were asked to complete a questionnaire on sociodemographic characteristics, attitude towards genetic testing, and intention to implement prevention strategies.
A total of 781 hospital-based women participated in this survey, including 516 (66.1%) women with BC and 265 (33.9%) without BC. Among the 516 participants with BC, the median age was 51 years (range, 22–87 years). Most participants had a low monthly income and education level. In addition, most women were married (97.5%) and had children (91.3%), while 13.4% had a family history of BC. Among the 265 participants without BC, the median age was 36 years (range, 13–90 years). Most participants without BC had a high monthly income and education level. Among women without BC, 78.9% were married and 63.8% had children and 10.6% had a family history of BC. The participant characteristics are summarized in Table S1.
Attitudes towards genetic testing
Less
Overall, 52.1% (n = 269) of the women with BC and 52.8% (n = 140) of the women without BC had favorable attitudes towards genetic testing but only 17.6% (n = 91) and 9.4% (n = 25) of women with and without BC underwent genetic testing, respectively. Interestingly, the proportion of participants who were inclined to undergo genetic testing increased if testing was free [women with BC (76.4%) vs. women without BC (77.7%)]. In addition, 22.9% (n = 118) of the women with BC and 14.3% (n = 38) of women without BC had received a genetic consultation (Table S2).
Factors influencing attitudes towards genetic testing
Less
Younger age (P = 0.003), higher monthly income (P < 0.001), higher education level (P = 0.001), having commercial insurance (P = 0.041), awareness of genetic testing (P < 0.001), and receiving a genetic consultation (P < 0.001) were correlated with favorable attitudes towards genetic testing for BC susceptibility genes in women with BC, while having commercial insurance (P = 0.010) and awareness of genetic testing (P = 0.024) remained favorable factors in women without BC (Table 1). Notably, a family history of BC had no significant impact in the two populations.
Motivations and concerns for genetic testing
Less
A high proportion (50.4%) of women with BC cited ‘To know children’s risk of inheriting PVs’ as the motivation for genetic testing, followed by ‘To know the possibility of personalized precision treatment’ (28.3%). A minority of women with BC chose ‘To know personal risk of BC’ (11.8%) and ‘To know personal risk-reducing prevention strategies’ (9.5%) as the motivations for genetic testing (Figure S2A). In contrast, about one-third women without BC (33.6%) cited ‘To know personal risk of BC’ as the main motivation for genetic testing. ‘To know children’s risk of inheriting PVs’ was the motivation for genetic testing among 27.5% of individuals. Approximately 20% of women without BC each reported ‘To know personal risk-reducing prevention strategies’ and ‘To know the possibility of personalized precision treatment’ as the motivation for genetic testing (Figure S2A).
Moreover, increasing the psychological burden of one’s children (46.1% vs. 34.3%) and oneself (28.5% vs. 42.3%) were the top two concerns for genetic testing in women with and without BC, respectively. Cost, as an important potential factor, was the third leading concern (10%–15%) for genetic testing. Few participants worried about the impact on insurance coverage (3.1% vs. 5.7%) or considered genetic testing not to be important (1.6% vs. 2.3%) in women with and without BC (Figure S2B).
Choices of prevention strategies
Less
Of women with BC when they were susceptibility gene PV carriers, 30.8% (n = 357) intended to undergo prophylactic mastectomy (Figure 1A). Furthermore, most women without BC when they were susceptibility gene PV carriers [53.2% (n = 141)] chose early detection, while fewer women considered risk-reducing prevention strategies with 24.9% (n = 66) choosing prophylactic mastectomy and 20.0% (n = 53) choosing chemoprevention. Only 1.9% (n = 5) of the participants chose not to utilize a prevention strategy (Figure 1B).
This was the first study to assess attitudes towards genetic testing for BC susceptibility genes and the choice of preventive strategies in Chinese women with and without BC. The current study revealed that > 50% of Chinese women with and without BC have favorable attitudes towards genetic testing but only 15% underwent genetic testing. The lower intention and utilization of genetic testing for BC in the Chinese population compared to Western populations might be due to regional and population differences.
Differences in motivations for genetic testing were noted between women with and without BC. Women with BC were more concerned about their children’s health, while women without BC cared more about their personal cancer risk, followed closely by their children’s health. It has been reported in other Asian populations that the leading motivations for genetic testing in women with BC and women who are cancer-free were to help the family understand the cancer risk and to learn what to do to reduce the individual cancer risk9.
There was a lower proportion of women [women with BC (30.8%) and women without BC (24.9%)] considering prophylactic mastectomy with a hypothetical susceptibility gene mutation in the current study compared to other studies. A study reported that > 50% of healthy young Korean women were inclined to undergo risk-reducing mastectomy if they were BRCA1/2 mutation carriers10. Another study found that 30% of young women with BC indicated that their knowledge or concern about genetic risk affected their surgical decisions. Among these women, 86% of BRCA1/2 mutation carriers and 51% of non-carriers chose bilateral mastectomy6. Culture differences and body image considerations might make the rate lower.
In summary, we found that > 50% of Chinese women have favorable attitude towards genetic testing. Nearly one-third of women with BC preferred to undergo prophylactic mastectomy and women without BC who carry PVs were more likely to prefer early detection. The results of the current study will facilitate genetic counseling in Chinese women.
Funding
Less
  • This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 82272932, 81974422, and 92359201).
References
Less
1.
Lei S,Zheng R,Zhang S,Chen R,Wang S,Sun K, et al.Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030.Cancer Biol Med.2021; 18: 900–9.
2.
Kuchenbaecker KB,Hopper JL,Barnes DR,Phillips K-A,Mooij TM,Roos-Blom M-J, et al.Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.JAMA.2017; 317: 2402–16.
3.
Li S,Silvestri V,Leslie G,Rebbeck TR,Neuhausen SL,Hopper JL, et al.Cancer risks associated with BRCA1 and BRCA2 pathogenic variants.J Clin Oncol.2022; 40: 1529–41.
4.
Zambelli A,Cortesi L,Gaudio M,Arpino G,Bianchini G,Caruso F, et al.Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: an Italian consensus paper and critical review.Cancer Treat Rev.2024; 130: 102815.
5.
Criscitiello C,Corti C.Breast cancer genetics: diagnostics and treatment.Genes (Basel).2022; 13: 1593.
6.
Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S, et al.BRCA1 and BRCA2 mutation testing in young women with breast cancer.JAMA Oncol.2016; 2: 730–6.
7.
Bruno M,Digennaro M,Tommasi S,Stea B,Danese T,Schittulli F, et al.Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women.Eur J Cancer Care (Engl).2010; 19: 360–8.
8.
Kurian AW,Griffith KA,Hamilton AS,Ward KC,Morrow M,Katz SJ, et al.Genetic testing and counseling among patients with newly diagnosed breast cancer.JAMA.2017; 317: 531–4.
9.
Chin TM,Tan SH,Lim SE,Iau P,Yong WP,Wong SW, et al.Acceptance, motivators, and barriers in attending breast cancer genetic counseling in Asians.Cancer Detect Prev.2005; 29: 412–8.
10.
Park B,Kim D,Kim J,Lee BY,Yoon J,Kim SW.Attitudes toward risk-reducing mastectomy and risk-reducing salpingo-oophorectomy among young, unmarried, healthy women in Korea.Cancer Res Treat.2022; 54: 375–82.
Appendix
Less
Year 2025 volume 22 Issue 1
PDF
7
4
Cite this Article
BibTeX
Article Info
doi: 10.20892/j.issn.2095-3941.2024.0519
  • Receive Date：2024-11-21
  • Online Date：2026-11-06
  • Published：2025-01-15
Article Data
Affiliations
History
  • Received：2024-11-21
  • Accepted：2025-01-02
Funding
This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 82272932, 81974422, and 92359201).
Affiliations
    1Department of Breast Surgery, Peking University International Hospital, Beijing 102206, China
    2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Comprehensive Clinical Trial Ward, Peking University Cancer Hospital & Institute, Beijing 100142, China
    3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Familial and Hereditary Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China

Corresponding:

Correspondence to: Yuntao Xie, E-mail:
References
Share
https://castjournals.cast.org.cn/joweb/cbm/EN/10.20892/j.issn.2095-3941.2024.0519
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House